Trastuzumab emtansine

BNF:
8.5.5
Status:
Red
Decision Date:
August 2017
 

Comments

RED 1,2,3: NICE TA458 (replaces NICE TA371 - negative appraisal): for treating HER2-postive advanced breast cancer after treatment with trastuzumab and a taxane. (Decision date - August 2017)

RED1,2,3: NICE TA632 - for adjuvant treatment of HER2-positive early breast cancer. (Decision date -  July 2020)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app